The fact that the cell permeable TAT‐ETD‐FLAG peptides, which, as we have previously shown, specifically inhibit HIF‐1 activity and trigger apoptosis in different cancer cell lines [11], efficiently disrupt the HIF‐1α/NPM1 association provides proof‐of‐principle that remains to be tested as a therapeutic intervention in vivo. The gene discussed is HIF1A; the disease is cancer.